**Medicare Part D Sample Letter of Tier Change Request**

Please Note: By downloading materials from this website, you agree to all of the following. These materials are available for download and public personal use. These materials have no value and are not to be re-sold or repurposed. They are solely for your personal use. No purchase from or relationship with IPSEN is required to download or use these materials. IPSEN makes no representations or warranties about these materials or their fitness for any specific use. IPSEN is not responsible for any changes made to these template documents. All billing and coding decisions are the responsibility of the relevant physician. IPSEN does not guarantee any specific reimbursement or favorable results.

|  |  |
| --- | --- |
| **[Insurance Company]****[Address]****[City, State, Zip]** | Re: **[Patient Name]****[Policy #]****[DOB]****[Address]****[City, State, Zip]** |
| To Whom It May Concern: I am writing on behalf of my patient, **[Patient Name, ID and Group Number]** to appeal for a tier change to a lower tier approval of **[Product name (generic name)] [SOMATULINE® DEPOT (lanreotide)], [DYSPORT® (abobotulinumtoxinA)], [ONIVYDE® (irinotecan liposome injection)], [INCRELEX® (mecasermin)]** associated with **[ICD10 Code]**.This letter of request for tier change approval includes the patient’s relevant past medical history, overview of prior care delivered, treatment rationale and supporting medical necessity data. The supporting data included with this letter confirms that a lower tier should be approved for the patient due to the rationale provided below.**Patient’s History, Past Treatments and Drugs Utilized (1500-character limit):** **[Include information outlining when the patient was diagnosed and severity of symptoms]**.**Treatment Rationale (1500-character limit):** **[Provide information on patient response to past treatments and anticipated prognosis and rationale for the currently prescribed product]**.**Supporting Study Data (1500-character limit):** **[Include references to published medical study data evaluating the use of the currently prescribed product. Remember to include the FDA approved indications and usage]**.In summary, the currently prescribed product is medically necessary for this patient’s medical condition and should be given a more favorable tier level for the patient. Please contact me if any additional information is required to ensure the prompt approval of the currently prescribed product at a lower tier for the patient. Sincerely, **[Physician Name and Signature]****[Phone #]**©2022 Ipsen Biopharmaceuticals, Inc. April 2022 MP-US-000426 V2.0 |